Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Chinook Therapeutics Company

KDNY
US16961L1061
A2QE43

Price

40.39
Today +/-
+0
Today %
+0 %
P

Chinook Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Chinook Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Chinook Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Chinook Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Chinook Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Chinook Therapeutics Stock Price History

DateChinook Therapeutics Price
8/18/202340.39 undefined
8/17/202340.39 undefined

Chinook Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Chinook Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Chinook Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Chinook Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Chinook Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Chinook Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Chinook Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Chinook Therapeutics’s growth potential.

Chinook Therapeutics Revenue, EBIT and net profit per share

DateChinook Therapeutics RevenueChinook Therapeutics EBITChinook Therapeutics Net Income
2028e688.21 M undefined0 undefined266.84 M undefined
2027e401.71 M undefined4.17 M undefined42.11 M undefined
2026e192.59 M undefined-142.94 M undefined-109.31 M undefined
2025e81.11 M undefined-259.45 M undefined-203.34 M undefined
2024e13.28 M undefined-288.26 M undefined-252.77 M undefined
2023e2.9 M undefined-246.71 M undefined-235.09 M undefined
20226.13 M undefined-185.08 M undefined-187.87 M undefined
202151.63 M undefined-106.27 M undefined-102.94 M undefined
2020830,000 undefined-54.71 M undefined-81.62 M undefined
201917.26 M undefined-83.93 M undefined-82.37 M undefined
201815.09 M undefined-97.37 M undefined-95.36 M undefined
201717.24 M undefined-106.45 M undefined-91.86 M undefined
201650.68 M undefined-71.86 M undefined-91.15 M undefined
201572.98 M undefined-13.56 M undefined-39.21 M undefined
201413.39 M undefined-19.12 M undefined-17.01 M undefined
2013830,000 undefined-14.54 M undefined-16.05 M undefined
2012290,000 undefined-10.11 M undefined-9.22 M undefined

Chinook Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e
00137250171517051621381192401688
---453.85-30.56-66.00-11.7613.33---88.24-66.67550.00523.08137.04108.8571.57
-----------------
00000000000000000
-10-14-19-13-71-106-97-83-54-106-185-246-288-259-14240
---146.15-18.06-142.00-623.53-646.67-488.24--207.84-3,083.33-12,300.00-2,215.38-319.75-73.961.00-
-9-16-17-39-91-91-95-82-81-102-187-235-252-203-10942266
-77.786.25129.41133.33-4.40-13.68-1.2225.9383.3325.677.23-19.44-46.31-138.53533.33
12.4612.4612.468.9413.0414.5815.7616.0213.1745.6164.37000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Chinook Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Chinook Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20122013201420152016201720182019202020212022
                     
3.78.5119.5415.7347.4326.1266.4213.6247.4286.84378.33
00.43.24.81.11120.30.310.061.09
0000017.500000
00000000000
0.20.52.646.25.54.546.43.746.18
3.99.4125.3424.5354.7350.1282.9217.9254.1300.64385.59
0.40.41.1426.431.129.245.876.374.3265.88
00015.414.523.611.403117.6252.26
00000000000
00029.427.831.125.1196762.5660.84
0008.57.78.78.38.222.40.120.12
00.10.20.17.50.50.50.56.28.559.4
0.40.51.357.483.99574.573.5174.9263.16188.49
4.39.9126.6481.9438.6445.1357.4291.4429563.8574.08
                     
23.732.21400000000.010.01
0.95.90.3362.8420.9519.4538.9552.1463.4685.46864.73
-28.6-44.6-61.6-100.9-192-283.9-404.5-486.9-128.8-231.77-419.63
000-0.3-1.71.90.90.40-0.06-3.16
00000000000
-4-6.578.7261.6227.2237.4135.365.6334.6453.64441.94
1.40.855.12.21.21.50.448.589.75
0.825.810.912.618.512.414.217.821.5138.58
011.633.41515.921.816.771102.5
00000000000
00000000000
2.214.444.23130.741.530.621.622.840.0950.84
10010010000000000
0007.45.96.56.13.516.40.745.08
61.93.5181.8174.9159.7185.6200.655.269.3476.23
6.123.6189.2180.8166.2191.7204.171.670.0881.31
8.316.447.8220.2211.5207.7222.3225.794.4110.16132.14
4.39.9126.5481.8438.7445.1357.6291.3429563.8574.08
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Chinook Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Chinook Therapeutics's financial health and stability.

Assets

Chinook Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Chinook Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Chinook Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Chinook Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
-9-16-17-39-91-91-95-82-81-102-187
00002454145
0000-760-2-224
1037158-2-270-3-8-519
01-13512192118381261
00000000000
0000-22,0001,00000000
-8-1419154-86-88-68-65-55-102-117
000-2-23-5-2-10-1-1
000-298-328839-1109-112-99
000-295-894410110-110-98
00000000000
00000000000
2393173378110124175126
519921744382-10124209151
3160050-3003325
00000000000
-2411031-7582-31-66178-5-66
-8.6-14.418.6152.6-110-94.1-71.2-66.8-56.6-104.62-119.13
00000000000

Chinook Therapeutics stock margins

The Chinook Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chinook Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chinook Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Chinook Therapeutics's sales revenue. A higher gross margin percentage indicates that the Chinook Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Chinook Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Chinook Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Chinook Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Chinook Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Chinook Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Chinook Therapeutics Margin History

Chinook Therapeutics Gross marginChinook Therapeutics Profit marginChinook Therapeutics EBIT marginChinook Therapeutics Profit margin
2028e0 %0 %38.77 %
2027e0 %1.04 %10.48 %
2026e0 %-74.22 %-56.76 %
2025e0 %-319.86 %-250.68 %
2024e0 %-2,171.11 %-1,903.81 %
2023e0 %-8,515.97 %-8,114.97 %
20220 %-3,020.28 %-3,065.68 %
20210 %-205.84 %-199.39 %
20200 %-6,591.57 %-9,833.74 %
20190 %-486.27 %-477.23 %
20180 %-645.26 %-631.94 %
20170 %-617.46 %-532.83 %
20160 %-141.79 %-179.85 %
20150 %-18.58 %-53.73 %
20140 %-142.79 %-127.04 %
20130 %-1,751.81 %-1,933.73 %
20120 %-3,486.21 %-3,179.31 %

Chinook Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Chinook Therapeutics earnings per share therefore indicates how much revenue Chinook Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Chinook Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chinook Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chinook Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chinook Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chinook Therapeutics Revenue, EBIT and net profit per share

DateChinook Therapeutics Sales per ShareChinook Therapeutics EBIT per shareChinook Therapeutics Earnings per Share
2028e9.58 undefined0 undefined3.72 undefined
2027e5.59 undefined0 undefined0.59 undefined
2026e2.68 undefined0 undefined-1.52 undefined
2025e1.13 undefined0 undefined-2.83 undefined
2024e0.18 undefined0 undefined-3.52 undefined
2023e0.04 undefined0 undefined-3.27 undefined
20220.1 undefined-2.88 undefined-2.92 undefined
20211.13 undefined-2.33 undefined-2.26 undefined
20200.06 undefined-4.15 undefined-6.2 undefined
20191.08 undefined-5.24 undefined-5.14 undefined
20180.96 undefined-6.18 undefined-6.05 undefined
20171.18 undefined-7.3 undefined-6.3 undefined
20163.89 undefined-5.51 undefined-6.99 undefined
20158.16 undefined-1.52 undefined-4.39 undefined
20141.07 undefined-1.53 undefined-1.37 undefined
20130.07 undefined-1.17 undefined-1.29 undefined
20120.02 undefined-0.81 undefined-0.74 undefined

Chinook Therapeutics business model

Chinook Therapeutics Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics to treat diseases involving inadequate or faulty kidney function, as well as immune and inflammatory mechanisms. The headquarters of Chinook Therapeutics is located in Seattle, Washington, USA. The company was founded in 2019 by a team of experienced executives in the biotechnology industry, including Tom Frohlich, former Vice President at Omeros Corporation, and Eric Dobmeier and Yi Liu, both formerly with Juno Therapeutics. Chinook Therapeutics aims to improve treatment options for patients with kidney diseases by developing novel therapeutics that influence kidney metabolism and the function of immune and inflammatory mechanisms. Chinook's products are intended to have the potential to slow down or stop the progression of kidney diseases and improve patients' lives. Chinook Therapeutics' business model focuses on supporting the discovery and development of potential therapeutics in the earliest stages to optimize the prospects of later commercialization. The company pursues a pipeline-based strategy that includes a variety of development programs with different focuses. The various divisions of Chinook Therapeutics include the following areas: 1. Therapeutic products for kidney diseases Chinook Therapeutics focuses on the discovery and development of therapeutics for kidney diseases targeting various aspects of kidney metabolism. An example of this is the drug candidate BION-1301, an antibody targeting the binding site of APRIL and BAFF on CD40, with the goal of controlling the progression of glomerulonephritis. 2. Immunology and anti-inflammatory therapeutics Chinook Therapeutics is also specialized in the discovery and development of therapeutics targeting the control of immune and inflammation-related diseases. An example of this is the drug candidate CHN-083, a potent inhibitor of the kinase TRPM8, specifically designed for pain relief in inflammatory conditions. 3. Partnerships with other companies Chinook Therapeutics also collaborates closely with other biotechnology companies and research institutions to accelerate the development of therapeutics and enable the commercialization of innovative products. One such partnership is with Arrowhead Pharmaceuticals, whose RNAi technology Chinook can utilize for developing therapeutics for rare diseases as well as kidney and urinary tract disorders. Chinook Therapeutics has established itself as an innovative biotechnology company driving the development of novel therapeutics in the areas of kidney diseases, immunology, and inflammation. The company relies on a pipeline-based strategy and works closely with other companies and research institutions to efficiently bring its developments to the market. Chinook Therapeutics is one of the most popular companies on Eulerpool.com.

Chinook Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Chinook Therapeutics Revenue by Segment

Segmente20192018
Collaboration and license revenue17.26 M USD18.3 M USD

Chinook Therapeutics SWOT Analysis

Strengths

1. Experienced Management Team: Chinook Therapeutics benefits from a skilled and knowledgeable leadership team with experience in the biopharmaceutical industry.

2. Strong Financial Position: The company has secured significant funding and capital investments, providing a solid foundation for research, development, and expansion.

3. Robust Pipeline: Chinook Therapeutics has a diverse portfolio of innovative drug candidates, targeting various diseases and disorders, which offers potential for future commercial success.

Weaknesses

1. Reliance on Partnerships: The company heavily depends on collaborations and partnerships to advance its drug candidates, which could lead to potential delays or challenges in decision-making.

2. Limited Market Presence: Compared to established competitors, Chinook Therapeutics has a relatively small market presence, which might pose difficulties in gaining market share and brand recognition.

3. Regulatory Hurdles: The biopharmaceutical industry faces stringent regulatory requirements, and any delays or failures in obtaining necessary approvals could negatively impact the company's timeline and profitability.

Opportunities

1. Growing Demand for Kidney Disease Therapeutics: The prevalence of kidney-related disorders is on the rise globally, presenting a significant market opportunity for Chinook Therapeutics, particularly with its focus on precision medicine.

2. Advancements in Precision Medicine: Rapid developments in the field of precision medicine offer potential breakthroughs in personalized treatments, providing an opportunity for Chinook Therapeutics to capitalize on its scientific expertise.

3. Expansion into Emerging Markets: There is a growing pharmaceutical market in emerging economies, presenting opportunities for Chinook Therapeutics to expand its reach and tap into new patient populations.

Threats

1. Intense Competition: The biopharmaceutical industry is highly competitive, with numerous established companies and new entrants, leading to potential challenges in gaining market share and profitability.

2. Intellectual Property Risks: Protecting intellectual property rights is crucial, as competitors may attempt to replicate or infringe upon Chinook Therapeutics' innovative drug candidates, potentially affecting the company's market position and revenue.

3. Economic and Regulatory Uncertainties: Changes in economic conditions or regulations, such as healthcare policy reforms, can significantly impact the market dynamics and financial viability of biopharmaceutical companies like Chinook Therapeutics.

Chinook Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Chinook Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Chinook Therapeutics shares outstanding

The number of shares was Chinook Therapeutics in 2023 — This indicates how many shares 64.37 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Chinook Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chinook Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chinook Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chinook Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chinook Therapeutics stock splits

In Chinook Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Chinook Therapeutics.

Chinook Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2023-0.83 -0.94  (-13.35 %)2023 Q2
3/31/2023-0.81 -0.85  (-4.85 %)2023 Q1
12/31/2022-0.81 -0.9  (-11.69 %)2022 Q4
9/30/2022-0.64 -0.83  (-30.05 %)2022 Q3
6/30/2022-0.63 -0.61  (2.49 %)2022 Q2
3/31/2022-0.68 -0.54  (20.51 %)2022 Q1
12/31/2021-0.69 0.14  (120.3 %)2021 Q4
9/30/2021-0.86 -0.69  (19.31 %)2021 Q3
6/30/2021-0.8 -1.14  (-42.68 %)2021 Q2
3/31/2021-0.69 -0.88  (-27.5 %)2021 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Chinook Therapeutics stock

Eulerpool World ESG Rating (EESG©)

55/ 100

🌱 Environment

60

👫 Social

58

🏛️ Governance

48

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Chinook Therapeutics shareholders

%
Name
Stocks
Change
Date
7.18876 % Samsara BioCapital, LLC5,161,888012/31/2022
6.05189 % Frazier Healthcare Partners4,345,55980,00012/31/2022
4.94397 % BlackRock Institutional Trust Company, N.A.3,550,018273,69712/31/2022
4.22701 % Versant Ventures3,035,207-400,0003/1/2023
4.17798 % Deep Track Capital LP3,000,000012/31/2022
3.87812 % The Vanguard Group, Inc.2,784,681392,80812/31/2022
3.70302 % State Street Global Advisors (US)2,658,956193,23712/31/2022
3.55366 % Octagon Capital Advisors LP2,551,703012/31/2022
3.52914 % Baker Bros. Advisors LP2,534,102012/31/2022
2.82613 % OrbiMed Advisors, LLC2,029,300012/31/2022
1
2
3
4
5
...
10

Chinook Therapeutics Executives and Management Board

Mr. Eric Dobmeier53
Chinook Therapeutics President, Chief Executive Officer, Director (since 2019)
Compensation 3.59 M
Mr. Tom Frohlich46
Chinook Therapeutics Chief Operating Officer
Compensation 1.87 M
Dr. Andrew King42
Chinook Therapeutics Chief Scientific Officer
Compensation 1.74 M
Dr. Jerel Davis45
Chinook Therapeutics Lead Independent Director
Compensation 170,986
Ms. Michelle Griffin56
Chinook Therapeutics Independent Director
Compensation 159,986
1
2
3

Chinook Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Merck & Co Stock
Merck & Co
SupplierCustomer0,70-0,120,230,050,09-0,26
Eli Lilly Stock
Eli Lilly
SupplierCustomer0,550,150,630,500,36-0,08
Hitgen A Stock
Hitgen A
SupplierCustomer0,23-0,36-0,070,03-0,28-0,06
AbbVie Stock
AbbVie
SupplierCustomer0,120,430,49-0,020,24-0,02
Evotec Stock
Evotec
SupplierCustomer-0,530,130,050,10-0,14-0,06
1

Most common questions regarding Chinook Therapeutics

What values and corporate philosophy does Chinook Therapeutics represent?

Chinook Therapeutics Inc represents values and a corporate philosophy focused on advancing precision medicine to develop transformative therapies for patients with kidney diseases and other rare disorders. By leveraging innovative science and strategic partnerships, Chinook aims to bring novel treatments to those in need. The company's core principles include a patient-centric approach, scientific rigor, collaboration, and commitment to improving patient outcomes. Through their dedication to addressing unmet medical needs, Chinook Therapeutics Inc strives to make a meaningful impact in the lives of patients worldwide.

In which countries and regions is Chinook Therapeutics primarily present?

Chinook Therapeutics Inc is primarily present in the United States and Canada.

What significant milestones has the company Chinook Therapeutics achieved?

Chinook Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in January 2020, raising substantial funds to support its research and development efforts. They have also entered into strategic partnerships and collaborations with industry leaders, enhancing their potential for breakthrough innovations. Notably, Chinook Therapeutics has made progress in advancing their pipeline of novel precision medicines focused on tackling kidney diseases, including the development of their lead candidate, BION-1301. These achievements demonstrate Chinook Therapeutics Inc's commitment to transforming the treatment landscape and improving the lives of patients affected by kidney-related conditions.

What is the history and background of the company Chinook Therapeutics?

Chinook Therapeutics Inc. is a cutting-edge biotechnology company focused on developing innovative therapies for kidney diseases. Founded in 2019, the company combines world-class expertise in kidney biology with proprietary insights into kidney targets. Chinook Therapeutics aims to tackle the significant unmet medical needs of patients with kidney diseases by advancing its portfolio of precision medicines. By leveraging strategic collaborations and a deep understanding of kidney biology, the company is dedicated to improving the lives of patients suffering from these debilitating conditions. With its talented team and transformative therapies, Chinook Therapeutics continues to make strides in the field of kidney disease treatment.

Who are the main competitors of Chinook Therapeutics in the market?

Some of the main competitors of Chinook Therapeutics Inc in the market include companies like Vertex Pharmaceuticals Inc, Reata Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

In which industries is Chinook Therapeutics primarily active?

Chinook Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries. As a leading company in the healthcare sector, Chinook is focused on developing precision medicines for patients with kidney diseases and other severe conditions. With its innovative approach and dedicated research efforts, Chinook Therapeutics Inc aims to address unmet medical needs and improve the lives of individuals affected by these illnesses. Through its groundbreaking therapies and advancements in the biotech field, Chinook is making significant contributions to the healthcare industry.

What is the business model of Chinook Therapeutics?

Chinook Therapeutics Inc is a biotechnology company focused on discovering and developing precision medicines for kidney diseases. Their business model revolves around utilizing advanced technologies and targeting specific pathways to identify and develop potential therapeutic solutions for patients with rare and common kidney disorders. By combining their expertise in kidney biology and precision medicine, Chinook Therapeutics aims to address the significant unmet medical needs in the field of kidney disease treatment. With a dedicated focus on innovative drug development and strategic partnerships, Chinook Therapeutics Inc strives to improve the lives of patients through their cutting-edge therapies.

What is the P/E ratio of Chinook Therapeutics 2024?

The Chinook Therapeutics P/E ratio is -10.29.

What is the P/S ratio of Chinook Therapeutics 2024?

The Chinook Therapeutics P/S ratio is 195.82.

What is the Quality Investing of Chinook Therapeutics?

The Quality Investing for Chinook Therapeutics is 5/10.

What is the revenue of Chinook Therapeutics 2024?

The expected Chinook Therapeutics revenue is 13.28 M USD.

How high is the profit of Chinook Therapeutics 2024?

The expected Chinook Therapeutics profit is -252.77 M USD.

What is the business model of Chinook Therapeutics

Chinook Therapeutics Inc is a biotechnology company specializing in the discovery and development of drugs for the treatment of rare and deadly kidney diseases. The company was founded in 2018 and is headquartered in Seattle, Washington. Chinook has built a comprehensive platform for the discovery and development of drugs based on genetic insights into kidney diseases and their progression. The company invests in targeted identification and validation of targets to identify new and innovative therapeutics that have the potential to change the treatment of kidney diseases. The business model of Chinook Therapeutics includes three main areas: research and development, clinical development, and partnerships. In the research and development area, Chinook invests in the identification and validation of new targets for the prevention and treatment of kidney diseases. Clinical development involves conducting clinical trials for new drugs to test their safety and efficacy in treating various medical conditions. Chinook currently has several promising drug candidates in various stages of clinical development, including appropriate patient populations for a genetically defined kidney disease. Chinook's partnerships with leading companies in the pharmaceutical and biotechnology industry have positive implications for the development and market launch of new medical products. Chinook collaborates with leading pharmaceutical companies for clinical trials and joint research projects to develop innovative drugs for patients. The company's broad portfolio includes a range of innovative therapeutics that have the potential to significantly improve the treatment of kidney diseases. The products include: BION-1301, an antibody targeting a pathway responsible for the progression of IgA nephropathy; CHK-336, a drug targeting the ApoL1 protein associated with kidney diseases and the progression of kidney diseases; and Speedy Study, a clinical trial investigating the use of Low-Dose Interleukin-2 (LDIL-2) for the treatment of lupus nephritis. Overall, Chinook Therapeutics has built a scientifically grounded business model that provides a strong foundation for the development and commercialization of novel therapeutics against kidney diseases. The investment in targeted identification and validation of targets, collaboration with leading researchers and key opinion leaders, and close cooperation with strategic partners in clinical trials will help Chinook successfully bring its innovative products to the market.

What is the Chinook Therapeutics dividend?

Chinook Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Chinook Therapeutics pay dividends?

The dividend cannot currently be calculated for Chinook Therapeutics or the company does not pay out a dividend.

What is the Chinook Therapeutics ISIN?

The ISIN of Chinook Therapeutics is US16961L1061.

What is the Chinook Therapeutics WKN?

The WKN of Chinook Therapeutics is A2QE43.

What is the Chinook Therapeutics ticker?

The ticker of Chinook Therapeutics is KDNY.

How much dividend does Chinook Therapeutics pay?

Over the past 12 months, Chinook Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chinook Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Chinook Therapeutics?

The current dividend yield of Chinook Therapeutics is .

When does Chinook Therapeutics pay dividends?

Chinook Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Chinook Therapeutics?

Chinook Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Chinook Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chinook Therapeutics located?

Chinook Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chinook Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chinook Therapeutics from 10/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/18/2024.

When did Chinook Therapeutics pay the last dividend?

The last dividend was paid out on 10/18/2024.

What was the dividend of Chinook Therapeutics in the year 2023?

In the year 2023, Chinook Therapeutics distributed 0 USD as dividends.

In which currency does Chinook Therapeutics pay out the dividend?

The dividends of Chinook Therapeutics are distributed in USD.

All fundamentals about Chinook Therapeutics

Our stock analysis for Chinook Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chinook Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.